+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 23 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating two new treatments compared to the best standard care for men with prostate cancer that has spread to other parts of the body and still responds to hormone therapy. This phase 3 trial includes multiple hospitals across the UK and is led by University College London. The study aims to see if adding targeted radiotherapy or a radioactive drug can slow cancer spread and improve survival. Participants are assigned by computer to one of several groups. One group receives standard care, which includes androgen deprivation therapy ADT plus other hormone therapies, possible chemotherapy with docetaxel, and local radiotherapy. Another group receives standard care plus targeted high-dose radiotherapy SABR to metastatic sites. A third group receives standard care plus a radioactive therapy called 177Lu-PSMA-617, given in cycles with two doses per cycle. Treatments continue unless side effects are severe or participants choose to stop. During the study, participants will have scans and tests to monitor their cancer and side effects. Doctors will check safety and treatment adherence over time. Researchers will measure overall survival, failure-free survival, progression-free survival, prostate cancer-specific survival, and quality of life up to 10 years from randomization. Safety will be closely monitored, and participants health will be followed during and after treatment.

Age: 18Years +MALEPhase 3
18 locations
P

Actively Recruiting

Researchers are studying adults aged 45 to 80 who have high levels of Lipoproteina, known as Lpa, a protein linked to higher risk of heart disease. The trial aims to compare the effects of lepodisiran, a drug given by injection, to a placebo on the amount and type of plaque in the hearts vessels using advanced imaging called Coronary Computed Tomography Angiography CCTA. This study is a Phase 3 randomized, double-blind trial focusing on treatment for cardiovascular disease or risk for a first cardiovascular event. Participants will receive either lepodisiran or a placebo by subcutaneous injection. The study will follow them for about 120 weeks, including assessments at baseline and at Week 104 to measure changes in noncalcified plaque volume in the coronary arteries. Secondary measures include changes in fat attenuation index, Lpa levels, participant feedback on the injection experience, and drug pharmacokinetics. During the study, participants will undergo imaging scans, blood tests, and questionnaires at scheduled times to track the effects of the drug compared to placebo. Researchers will monitor the plaque in coronary arteries and Lpa levels to understand how lepodisiran may impact cardiovascular health. Safety and participant experience with the treatment will also be assessed throughout the trial duration.

Age: 45Years - 80YearsAll GendersPhase 3
57 locations
P

Actively Recruiting

Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.

Age: 18Years +All GendersPhase 3
804 locations
A

Actively Recruiting

Researchers are studying patients with breast cancer who have limited nodal disease confirmed by biopsy and are undergoing primary surgery. The study evaluates targeted sentinel node biopsy TSNB as a method to assess axillary lymph node involvement and compares its outcomes to other staging methods. This observational audit aims to collect data on surgical results, arm lymphoedema, and disease progression, benchmarking against previous trials and current guidelines. Participants will undergo TSNB where the marked, biopsy-proven positive node is removed along with sentinel nodes, following standard local practices and protocols such as those used in the ATNEC trial. The marked node may be identified using clips, dyes, magnetic seeds, or other techniques. At least three nodes should be removed for adequate assessment. Further axillary treatment decisions after TSNB will be made by the treating multidisciplinary team based on local protocols. During the study, participants will be followed for up to 60 months with regular assessments of nodal metastases, identification rates of marked nodes, false negative rates, and arm lymphoedema. Secondary outcomes include axillary, regional, and local recurrence, disease-free survival, and overall survival. Data collection will include histology results and clinical follow-up to monitor outcomes and treatment effectiveness in this patient population.

Age: 18Years +All Genders
14 locations
S

Actively Recruiting

Researchers are evaluating whether skipping additional axillary treatment for patients with early-stage breast cancer who had cancer in their lymph nodes before chemotherapy but show no remaining cancer in those nodes after treatment is as effective as the standard approach. This study focuses on disease-free survival and reducing the risk of lymphoedema five years after treatment. It is a randomized, open, multicenter trial including patients with specific breast cancer stages and confirmed nodal metastases. Participants will all receive standard therapies including HER2-targeted treatment, endocrine therapy, and radiotherapy to the breast or chest wall if needed. They will be randomly assigned to one of two groups one group will not get further axillary treatment such as lymph node removal or radiotherapy, while the other group will receive these axillary treatments according to local guidelines. Follow-up visits will occur annually for at least five years. During the study, participants will undergo assessments to monitor disease-free survival and self-reported lymphoedema using specific questionnaires. Additional evaluations include arm function, quality of life, recurrence rates, survival, and cost-effectiveness analyses. The total study duration is planned for 120 months, including setup, recruitment, follow-up, analysis, and reporting.

Age: 18Years +All GendersPhase Not Applicable
98 locations
P

Actively Recruiting

Researchers are evaluating a co-designed balance training program called Sport4Steadiness S4S for people with Chronic Obstructive Pulmonary Disease COPD. The study aims to determine if the S4S program is acceptable to participants and if the study procedures, including recruitment and outcome collection, are feasible. It is a randomized controlled trial focusing on prevention in COPD patients with balance concerns. Participants are randomly assigned to one of two groups. One group continues with their usual home-based exercise program provided by pulmonary rehabilitation as part of standard care. The other group participates in the S4S balance training program, which involves group exercise sessions twice a week for six weeks. Each session lasts two hours, including one hour of balance activities adapted from sports and games to improve balance and one hour of social interaction. During the study, participants undergo assessments at the end of recruitment, after randomization, and approximately 12 weeks after the baseline assessment to evaluate the feasibility of the study procedures and the delivery of S4S. Researchers will monitor participants progress and collect data on balance and fall risk. The total study duration includes the intervention period plus follow-up assessments to understand the programs acceptability and practicality.

All AgesAll GendersPhase Not Applicable
3 locations
C

Actively Recruiting

Researchers are evaluating the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for treating pre- and postmenopausal women and men with locally advanced or metastatic estrogen receptor positive ERhuman epidermal growth factor 2 negative HER2- breast cancer that has an ESR1 mutation. This study focuses on patients who have previously received ribociclib or palbociclib-based treatment and aims to compare the effectiveness, safety, and tolerability of these two treatment combinations. Participants will receive either 5 mg per day of oral lasofoxifene plus oral abemaciclib 150 mg twice daily, or fulvestrant 500 mg given intramuscularly on Days 1, 15, and 29, then once monthly thereafter, combined with oral abemaciclib 150 mg twice daily. The study is randomized and open-label, allowing comparison between these two treatment combinations over time. During the study, participants will be closely monitored for progression-free survival, objective response rate, overall survival, clinical benefit rate, duration and time to response, time to cytotoxic chemotherapy, quality of life using a specific breast cancer assessment tool, and the incidence of adverse events. The study includes various assessments and safety monitoring over approximately three years to evaluate these outcomes and the participants response to the treatments.

Age: 18Years +All GendersPhase 3
224 locations
O

Actively Recruiting

Researchers are investigating a new way to treat patients with malignant pleural effusion, a condition where fluid builds up around the lungs causing breathlessness. The study aims to see if talc pleurodesis, a procedure to stop fluid buildup that usually requires hospital stay, can be safely done on an outpatient basis to improve quality of life. The study also collects patient feedback on the acceptability of this approach. Participants will have a chest drain inserted on the first day to remove fluid using a standard underwater seal bottle. The drain is clamped and opened repeatedly to remove fluid throughout the day before being connected to an ambulatory bag for the patient to go home. On the second day, fluid output is assessed, and if appropriate, talc slurry with lidocaine is instilled to prevent fluid return. The drain remains connected to the ambulatory bag as patients return home. On the third day, further fluid drainage and chest x-rays determine if the drain can be removed and the treatment completed. During the study, patients complete brief questionnaires about breathlessness, chest pain, and satisfaction with the procedure at multiple times on days 1 to 3 and again at day 30. Researchers will monitor the success of delivering the ambulatory talc pleurodesis protocol, patient satisfaction, and safety through chest x-rays and follow-up. The entire treatment and observation span about five days with ongoing follow-up after completion.

Age: 18Years +All GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are evaluating whether using MRI imaging for staging sigmoid colon adenocarcinoma can change treatment plans by detecting more high-risk tumors compared to standard CT imaging. This randomized phase II multicenter trial aims to improve radical treatment decisions and provide better prognostic information to patients. The study involves patients eligible for curative treatment whose MRI can be reviewed before surgery without a prior treatment decision. Participants are assigned randomly to one of three groups standard preoperative CT imaging with multidisciplinary team discussion, standard CT plus an additional preoperative MRI scan with team discussion, or observation only. The MRI provides supplementary diagnostic information that may alter treatment strategies based on local protocols. During the study, patients are followed up at 1 and 3 years with quality of life questionnaires. Researchers assess differences in cancer staging between CT and MRI, treatment changes, recurrence rates, disease-free survival, surgery quality, pathology outcomes, morbidity and mortality, and permanent stoma rates. The total follow-up extends up to 5 years after treatment, with outcomes measured at multiple time points to understand the impact of MRI staging on patient care.

Age: 16Years +All GendersPhase Not Applicable
16 locations
U

Actively Recruiting

Researchers are studying the use of magnetic resonance tumour regression grade mrTRG as a new imaging biomarker to guide treatment decisions for patients with locally advanced rectal cancer. This phase III trial is unique in the UK as it offers a watch and wait approach for patients showing a good response to preoperative treatment, potentially avoiding surgery. The trial aims to validate mrTRGs ability to identify patients who can safely defer surgery and those who may need intensified treatment, thus tailoring care based on MRI findings. Participants are randomly assigned to one of two groups. The control group receives management according to national guidelines with post-treatment MRI scans interpreted without mrTRG assessment. The intervention group has their post-treatment MRI scans evaluated by specially trained radiologists to assign an mrTRG grade. Patients with a good response mrTRG 1 & 2 are offered a watch and wait approach to avoid surgery, while those with a poor response mrTRG 3-5 have their cases reviewed by a local colorectal multidisciplinary team for further treatment planning and surveillance. Treatment decisions, including chemotherapy use, follow routine clinical practice and are documented but not dictated by the trial. Participants undergo regular monitoring for up to five years, including routine post-treatment MRI scans following the MERCURY protocol and quality of life questionnaires at registration, 3 years, and 5 years. The study assesses if surgery can be safely avoided after a good MRI response and tracks surgical outcomes, survival, quality of life, and economic impact. Additional evaluations include reproducibility of mrTRG readings, molecular and immunological markers, and circulating tumor DNA to predict relapse. This long-term follow-up aims to improve personalized treatment for rectal cancer patients.

Age: 16Years +All GendersPhase Not Applicable
10 locations

1-10 of 23

1